Bioventus Inc. (BVS) is a Medical - Devices company in the Healthcare sector, currently trading at $9.91. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BVS = $13.69 (+38.1% from the current price, the stock appears undervalued). Analyst consensus target is BVS = $13 (+31.2% upside).
Valuation: BVS trades at a trailing Price-to-Earnings (P/E) of 26.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.57.
Financials: revenue is $568M, +3.7%/yr average growth. Net income is $23M, growing at +82.6%/yr. Net profit margin is 4% (thin). Gross margin is 67.3% (+2.7 pp trend).
Balance sheet: total debt is $311M against $184M equity (Debt-to-Equity (D/E) ratio 1.69, leveraged). Current ratio is 1.7 (strong liquidity). Debt-to-assets is 45.5%. Total assets: $684M.
Analyst outlook: 4 / 6 analysts rate BVS as buy (67%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 79/100 (Pass), Growth 73/100 (Pass), Past 25/100 (Fail), Health 33/100 (Fail), Moat 64/100 (Partial), Future 73/100 (Pass), Income 30/100 (Fail).
